We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals
JAZZ

373 hedge funds and large institutions have $9.87B invested in Jazz Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 121 increasing their positions, 146 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 30

9% more capital invested

Capital invested by funds: $9.08B → $9.87B (+$788M)

5% more funds holding

Funds holding: 354 → 373 (+19)

17% less repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 146

28% less funds holding in top 10

Funds holding in top 10: 18 → 13 (-5)

52% less call options, than puts

Call options by funds: $54M | Put options by funds: $113M

Holders
373
Holders Change
+19
Holders Change %
+5.37%
% of All Funds
10.05%
Holding in Top 10
13
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-27.78%
% of All Funds
0.35%
New
51
Increased
121
Reduced
146
Closed
30
Calls
$54M
Puts
$113M
Net Calls
-$59.1M
Net Calls Change
-$28.4M

Top Buyers

1
BFA
BlackRock Fund Advisors
California
+$272M
2
BIT
BlackRock Institutional Trust
California
+$261M
3
PC
PointState Capital
New York
+$76.6M
4
BG
BlackRock Group
United Kingdom
+$71.1M
5
NC
Nicholas Company
Wisconsin
+$60.4M

Top Sellers

1
Wells Fargo
Wells Fargo
California
-$68.1M
2
JHIU
Janus Henderson Investors US
Colorado
-$65.5M
3
HM
HealthCor Management
New York
-$56.2M
4
LPC
Lone Pine Capital
Connecticut
-$45.1M
5
Franklin Resources
Franklin Resources
California
-$27.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
376
Allen Investment Management
New York
– -$13.8M -80,000 Closed
BJCM
377
Blue Jay Capital Management
California
– -$11.2M -65,000 Closed
PP
378
PDT Partners
New York
– -$8.01M -46,381 Closed
Victory Capital Management
379
Victory Capital Management
Texas
– -$7.32M -42,335 Closed
TCM
380
Timpani Capital Management
Wisconsin
– -$3.44M -19,918 Closed
MTB
381
Mizuho Trust & Banking
Japan
– -$3.32M -19,225 Closed
HIP
382
Hatteras Investment Partners
North Carolina
– -$1.62M -9,384 Closed
SFP
383
Santa Fe Partners
New Mexico
– -$1.55M -8,964 Closed
Jacobs Levy Equity Management
384
Jacobs Levy Equity Management
New Jersey
– -$1.33M -7,678 Closed
Creative Planning
385
Creative Planning
Kansas
– -$1.32M -7,658 Closed
VAM
386
Visium Asset Management
New York
– -$535K -3,098 Closed
ARC
387
Absolute Return Capital
Massachusetts
– -$485K -2,807 Closed
MSU
388
Maple Securities USA
New Jersey
– -$467K -2,705 Closed
SEC
389
Seven Eight Capital
New York
– -$467K -2,700 Closed
CIM
390
Calvert Investment Management
Maryland
– -$459K -2,659 Closed
EGM
391
Engineers Gate Manager
New York
– -$354K -2,049 Closed
ID
392
Integral Derivatives
New York
– -$346K -2,001 Closed
SAM
393
Symphony Asset Management
California
– -$274K -1,583 Closed
BAAM
394
Baker Avenue Asset Management
California
– -$249K -1,440 Closed
PCM
395
Price Capital Management
Louisiana
– -$247K -1,428 Closed
PG
396
PEAK6 Group
Illinois
– -$201K -1,121 Closed
CIM
397
CenturyLink Investment Management
Colorado
– -$107K -622 Closed
WRM
398
Westport Resources Management
Connecticut
– -$86K -500 Closed
FM
399
Forward Management
California
– -$52K -300 Closed
WCM
400
Wealthcare Capital Management
Virginia
– -$53.9K -300 -92%
13 14 15
16
17

JAZZ Hedge Fund Activity: Q2 2015 in Review

373 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2015, worth a combined $9.87B — up 8.7% from $9.08B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new JAZZ positions and 30 closed out — a net gain of 21 holders — while 121 added to existing stakes and 146 trimmed.

The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $272M. The largest seller was Wells Fargo, cutting an estimated $68.1M.

  • 373 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2015, up from 354 in Q1 2015.
  • Funds reported $9.87B of Jazz Pharmaceuticals stock for Q2 2015, up 8.7% quarter-over-quarter.
  • 51 funds opened new Jazz Pharmaceuticals positions in Q2 2015 and 30 closed out, a net change of +21 holders.
  • The largest Jazz Pharmaceuticals buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $272M added.
  • The largest Jazz Pharmaceuticals seller in Q2 2015 was Wells Fargo, an estimated $68.1M sold.

Based on aggregated 13F filings for Q2 2015.